期刊
JOURNAL OF CLINICAL MICROBIOLOGY
卷 59, 期 1, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.00583-20
关键词
clinical study; MinION; Mycobacterium tuberculosis; nanopore; public health laboratories; whole-genome sequence
类别
资金
- National Institute of Allergy and Infectious Diseases [5R21AI13985602]
- Wadsworth Center Advanced Genomic Technologies
The study assessed the feasibility of using nanopore sequencing for Mycobacterium tuberculosis and compared the results with Illumina MiSeq sequencing. The results showed that nanopore sequencing can achieve comparable levels of genotyping analysis and drug resistance predictions at a competitive cost per sample, making it a suitable alternative or complement to current sequencing platforms in a clinical setting.
Next-generation sequencing technologies are being rapidly adopted as a tool of choice for diagnostic and outbreak investigation in public health laboratories. However, costs of operation and the need for specialized staff remain major hurdles for laboratories with limited resources for implementing these technologies. This project aimed to assess the feasibility of using Oxford Nanopore MinION whole-genome sequencing data of Mycobacterium tuberculosis isolates for species identification, in silico spoligotyping, detection of mutations associated with antimicrobial resistance (AMR) to accurately predict drug susceptibility profiles, and phylogenetic analysis to detect transmission between cases. The results were compared prospectively in real time to those obtained with our current clinically validated Illumina MiSeq sequencing assay for M. tuberculosis and phenotypic drug susceptibility testing results when available. Our assessment of 431 sequenced samples over a 32-week period demonstrates that, when using the proper quality controls and thresholds, the MinION can achieve levels of genotyping analysis and phenotypic resistance predictions comparable to those of the Illumina MiSeq at a very competitive cost per sample. Our results indicate that nanopore sequencing can be a suitable alternative to, or complement, currently used sequencing platforms in a clinical setting and has the potential to be widely adopted in public health laboratories in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据